Hi-Risk/Recurrent/Advanced PCa Video Chat, Apr 3, 2023

by Rick Davis | Apr 4, 2023 | Cancer Resources, mCRPC, mHSPC, nmCRPC, Prostate Cancer, Recorded Groups

Hi-Risk/Recurrent/Advanced PCa Video Chat, Apr 3, 2023

AnCan is grateful to the following sponsors for making this recording posssible: Bayer, Foundation Medicine, Pfizer, Janssen, Myriad Gentics, Myovant & Telix

WEBINAR RECORDING: What is a Pelvic Floor Physical Therapist – & why you need one https://ancan.org/webinar-what-is-a-pelvic-floor-physical-therapist-and-why-you-need-one/

All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/    Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups: Men (Only) Speaking Freely …1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/   Veterans Healthcare … 4th Thursday @ 8.00 pm Eastern https://ancan.org/veterans/

Editor’s pick: Hang in to the end when we have a good discussion around BCR – biochemical recurrence. (RD)

Topics Discussed

Update on Professor Herb; recurrence in BRCA+ man reluctant to undergo salvage RT; firsthand experience with pelvic floor therapy; how does testosterone recover post HT; more chemo vs worsening side effects as PSA plateaus around nadir; what type of RT is being used for salvage?; with Pluvicto shortage, maybe Xofigo first?; Pluvicto triage update; T comes back and PSA moves a tad post treatment; deciding whether to complate Pluvicto cycle; when to intervene post RP as PSA inches upwards; what constitutes biochemical recurrence?;

Chat Log

Ben https://www.urotoday.com/video-lectures/prostate-cancer/video/2721-the-embark-study-a-phase-3-randomized-study-of-enzalutamide-plus-leuprolide-and-enzalutamide-monotherapy-in-high-risk-nonmetastatic-hormone-sensitive-prostate-cancer-with-rising-psa-after-local-therapy-stephen-freedland.html

Ben sent · 5:55 PM An important element of EMBARK was that study treatment was suspended once the PSA was less than 0.2 or if it was less than 0.2 at week 36 and then restarted when the PSA was greater than or equal to five for those without prior radical prostatectomy and greater than or equal a two with those who had received primary prostatectomy.

AnCan- rick sent · 6:06 PM Webinar …. Pelvic Floor Webinar https://ancan.org/webinar-what-is-a-pelvic-floor-physical-therapist-and-why-you-need-one/

Terrill SF sent · 6:08 PM must leave early…see you all next time

Anthony Pizzoferrato sent · 6:11 PM I will listen to the video for any more information. Need to go. Thanks everyone.

Anthony Bill Franklin sent · 6:20 PM Wang Gao Shan, also, don’t worry too much about the number but more about how you feel and what you can do. Prior to my treatment my T levels were always over 600. Post treatment it never came back higher than 350 but I really can’t tell the difference. Still very active physically and sexually and no worries. It’s all how you feel.

Jack sent · 6:22 PM excessive B-6 can interfere with the effectiveness of cisplatin.

Frank Fabish Columbus OH sent · 6:31 PM Got to go. Thanks guys.

Mark Thompson, Rehoboth Beach, DE sent · 6:35 PM Thank you all for a great discussion tonight. I have several doctors appointments tomorrow so I am going to bed. Still dealing with extreme fatigue. Thank you, Mark Thompson

Bob G sent · 6:57 PM Oh! will send an email with some ideas

Julian – Houston sent · 6:59 PM Another great discussion. Thanks everyone. Good night.

sent · 7:00 PM Nice meeting everyone. Thank you for the support and constructive input. Be safe. Stay strong.

Don Eisner sent · 7:01 PM Have to leave

Ben Nathanson sent · 7:01 PM PSA persistence/recurrence after RP is defined as * failure of PSA to fall to undetectable levels (PSA persistence) or * undetectable PSA after RP with a subsequent detectable PSA that increases on 2 or more determinations (PSA recurrence) or that * increases to PSA less than 0.1 ng/mL. RTOG-ASTRO (Radiation Therapy Oncology Group – American Society for Therapeutic Radiology and Oncology) Phoenix Consensus: 1) PSA increase by 2 ng/mL or more above the nadir PSA is the standard definition for PSA recurrence after EBRT with or without HT; and 2) A recurrence evaluation should be considered when PSA has been confirmed to be increasing after radiation even if the increase above nadir is not yet 2 ng/mL, especially in candidates for salvage local therapy who are young and healthy.

John A sent · 7:10 PM sorry to leave mid discussion guys, gotta go

Joe Comanda sent · 7:13 PM What is the proper approach to ask questions in this group: 1) save them up for the next meeting or 2) send email questions or 3) put them in this chat list?

AnCan- rick sent · 7:13 PM https://www.houstonmethodist.org/doctor/eleni-efstathiou/?inm=vfad